中文

Journal of Shanghai University >

2016 , Vol. 22 >Issue 3: 376 - 380

DOI: https://doi.org/10.3969/j.issn.1007-2861.2016.03.020

Clinic significance of D-dimer in short-term prognosis of patients with acute heart failure

Expand
  • Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Received date: 2016-04-22

  Online published: 2016-06-30

Fold

Abstract

This paper investigates the clinic significance of D-dimer in short-term prognosis of patients with acute heart failure (AHF). A total of 206 patients with AHF were enrolled and followed up for 3 months. Baseline level of complete blood count, complete biochemistry, D-dimer and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured at admission or in the following morning. Primary endpoints of the study were cardiovascular (CV) events, defined as cardiac death and/or readmission for AHF. D-dimer and NT-proBNP were significantly higher in the patients who had a CV events in a 90-day period (P < 0.001). The analysis results of the receiver operating characteristic (ROC) curves showed that the area under the curves (AUCs) of NT-proBNP, and D-dimer for predicting CV events within 90 days were 0.806 and 0.887. Kaplan-Meier survival curves for the 90-day CV events showed that patients with a D-dimer level > 1.1 mg/dL and NT-proBNP level > 2 262.0 pg/mL were at high risk (P < 0.001) for short-term outcomes of AHF. D-dimer can be used as a new biomarker to enhance the value in early predicting cardiovascular events of AHF when combined with NT-proBNP.

Key words：  D-dimer;  prognosis; acute heart failure (AHF)

Cite this article

ZHANG Jialiang, GAO Rongrong, LI Xinli, WANG Hui . Clinic significance of D-dimer in short-term prognosis of patients with acute heart failure[J]. Journal of Shanghai University, 2016 , 22(3) : 376 -380 . DOI: 10.3969/j.issn.1007-2861.2016.03.020

References

[1] Braunwald E. Heart failure [J]. JACC Heart Failure, 2013, 1(1): 1-20.
[2] Daniels L B, Maisel A S. Natriuretic peptides [J]. Journal of the American College of Cardiology, 2007, 50(25): 2357-2368.
[3] Maisel A, Mueller C, Adams K F, et al. State of the art: using natriuretic peptide levels in clinical practice [J]. European Journal of Heart Failure, 2008, 10(9): 824-839.
[4] Tang Y D, Katz S D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options [J]. Circulation, 2006, 113(20): 2454-2461.
[5] Felker G M, Adams K F, Gattis W A, Jr., et al. Anemia as a risk factor and therapeutic target in heart failure [J]. Journal of the American College of Cardiology, 2004, 44(5): 959-966.
[6] Kalantar-Zadeh K, Anker S D, Horwich T B, et al. Nutritional and anti-inflammatory interventions in chronic heart failure [J]. American Journal of Cardiology, 2008, 101(11A): 89E-
103E.
[7] He W, Jia J, Chen J, et al. Comparison of prognostic value of red cell distribution width and NT-proBNP for short-term clinical outcomes inacute heart failure patients [J]. International Heart Journal, 2014, 55(1): 58-64.
[8] Darze E S, Latado A L, Guimaraes A G, et al. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients [J]. Chest, 2007, 131(6): 1838-1843.
[9] Ng T M, Tsai F, Khatri N, et al. Venous thromboembolism in hospitalized patients with heart failure: incidence, prognosis, and prevention [J]. Circulation Heart Failure, 2010, 3(1): 165-173.
[10] 李珊珊, 高蓉蓉, 张海锋, 等. sST2和半乳糖凝集素3对急性心力衰竭短期预后的预测价值[J]. 江苏医药, 2016, 42(4): 402-404.

Options
Outlines

/

〈 〉